Form 4: FibroGen CEO Wettig Sells Shares to Cover Tax Obligations

FibroGen CEO Thane Wettig sold 2,363 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• FibroGen CEO Thane Wettig sold 2,363 shares of common stock on December 6, 2024.
• The sale was executed at a price of $0.3421 per share.
• This transaction was to cover tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Wettig directly owns 419,953 shares of FibroGen common stock.
• Wettig also indirectly owns 1,000 shares through a spouse.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for executives who receive stock-based compensation.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US.
• The transaction is typical for executives who receive stock as part of their compensation and need to cover tax liabilities upon vesting.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

FibroGen, FGEN, Thane Wettig, CEO, stock sale, Form 4, insider trading, restricted stock units, tax obligations